Literature DB >> 5929693

T-strain Mycoplasma. Selective inhibition by erythromycin in vitro.

M C Shepard, C D Lunceford, R L Baker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1966        PMID： 5929693      PMCID： PMC1047768          DOI： 10.1136/sti.42.1.21

Source DB:  PubMed          Journal:  Br J Vener Dis        ISSN： 0007-134X


× No keyword cloud information.
  12 in total

1.  Mycoplasma pneumoniae: proposed nomenclature for atypical pneumonia organism (Eaton agent).

Authors:  R M CHANOCK
Journal:  Science       Date:  1963-05-10       Impact factor: 47.728

2.  Genital strains of human pleuropneumonia-like organisms.

Authors:  D K FORD; M DUVERNET
Journal:  Br J Vener Dis       Date:  1963-03

3.  T-strain pleuropneumonia-like organisms as one cause of non-gonococcal urethritis.

Authors:  D K FORD; G RASMUSSEN; J MINKEN
Journal:  Br J Vener Dis       Date:  1962-03

4.  Pleuropneumonia-like organisms in genital infections.

Authors:  E KLIENEBERGER-NOBEL
Journal:  Br Med J       Date:  1959-01-03

5.  Erythromycin in nonspecific urethritis.

Authors:  R R WILLCOX
Journal:  Lancet       Date:  1954-10-02       Impact factor: 79.321

6.  The effects of the administration of erythromycin upon Neisseria gonorrhoeae and pleuropneumonia-like organisms in the uterine cervix.

Authors:  A RUBIN; N L SOMERSON; P F SMITH; H E MORTON
Journal:  Am J Syph Gonorrhea Vener Dis       Date:  1954-09

7.  The recovery of pleuropneumonia-like organisms from Negro men with and without nongonococcal urethritis.

Authors:  M C SHEPARD
Journal:  Am J Syph Gonorrhea Vener Dis       Date:  1954-03

8.  Role of organisms of the pleuropneumonia group in human genital infections.

Authors:  C S NICOL; D G EDWARD
Journal:  Br J Vener Dis       Date:  1953-09

9.  Susceptibilities of Kazan, Nichols, and Reiter strains of Treponema and pleuropneumonia-like organisms to the antibiotic erythromycin (ilotycin).

Authors:  R KELLER; H E MORTON
Journal:  Am J Syph Gonorrhea Vener Dis       Date:  1953-07

10.  EFFECT OF PH ON HUMAN MYCOPLASMA STRAINS.

Authors:  M C SHEPARD; C D LUNCEFORD
Journal:  J Bacteriol       Date:  1965-02       Impact factor: 3.490
View more
  9 in total

1.  Lincomycin, non-gonococcal urethritis, and mycoplasmata.

Authors:  G W Csonka; R J Spitzer
Journal:  Br J Vener Dis       Date:  1969-03

2.  Antimicrobial susceptibility of Ureaplasma urealyticum.

Authors:  J W Davis; B A Hanna
Journal:  J Clin Microbiol       Date:  1981-02       Impact factor: 5.948

3.  Occurrence of urease in T strains of Mycoplasma.

Authors:  M C Shepard; C D Lunceford
Journal:  J Bacteriol       Date:  1967-05       Impact factor: 3.490

4.  Standardized method for determining antimicrobial susceptibility of strains of Ureaplasma urealyticum and their response to tetracycline, erythromycin, and rosaramicin.

Authors:  J A Robertson; J E Coppola; O R Heisler
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

5.  Mechanisms of macrolide resistance in Ureaplasma urealyticum: a study on collection and clinical strains.

Authors:  G Palù; S Valisena; M F Barile; G A Meloni
Journal:  Eur J Epidemiol       Date:  1989-06       Impact factor: 8.082

6.  In vitro susceptibility of Ureaplasma urealyticum to rosaramicin.

Authors:  T F Smith
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

7.  Susceptibility of genital mycoplasmas to antimicrobial agents.

Authors:  P Braun; J O Klein; E H Kass
Journal:  Appl Microbiol       Date:  1970-01

8.  Possible Mycoplasma hominis urethritis rvealed by differing responses of "abacterial urethritis" to treatment with tetracycline and erythromycin.

Authors:  A S Grimble
Journal:  Br J Vener Dis       Date:  1968-09

9.  Evaluation of the MYCOPLASMA IST3 urogenital mycoplasma assay in an international multicentre trial.

Authors:  Ian Boostrom; Yohan Bala; Jelena Minic Vasic; Jelena Gluvakov; Emmanuel Chanard; Andrew H Barratt; Kirsty Sands; Edward Portal; Laurence Devigne; Lucy C Jones; Owen B Spiller
Journal:  J Antimicrob Chemother       Date:  2021-11-12       Impact factor: 5.790
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.